In summary, the molecular profiling of IDHi-treated AML samples revealed that leukemia stemness plays major role in primary resistance to the drug, whereas co-occurring mutations, particularly in hematopoietic TF genes (RUNX1 and CEBPA) and RAS-RTK genes, are critical factors for acquired resistance. Here, CEBPA is linked to leukemia.